Kamada Launches New Plasma Collection Center in Houston
Kamada Ltd., a prominent global biopharmaceutical company, has just opened a cutting-edge plasma collection center in Houston. This launch is part of Kamada's strategy to boost its operational capacity within the specialty plasma-derived sector, which addresses medical conditions that currently lack sufficient treatment options. The new facility is expected to be one of the largest plasma collection sites for specialty treatments in the United States, marking a significant milestone for the company.
New Center Overview
The new center covers 12,000 square feet and includes more than 50 donor beds, enhancing Kamada Plasma's collection capabilities substantially. It is projected to collect around 50,000 liters of plasma each year, potentially generating between $8 million and $10 million in annual revenue when fully operational. Most of this income will come from the collection of normal source plasma, which is vital for various biopharmaceutical uses.
Kamada's Goals for Specialty Plasma Collection
Amir London, Kamada's CEO, stated that the Houston center greatly enhances the company’s vertical integration and its ability to process specialty plasma, including critical products like Anti-Rabies and Anti-D plasma. Gathering these specialized products is essential for patients with specific health issues that require immediate therapeutic solutions.
Plans for Further Expansion
Kamada's expansion plans extend beyond the Houston center. The company is also in the process of developing a third plasma collection site in San Antonio, Texas, which is set to begin operations in the near future. This ongoing growth underlines Kamada's dedication to building a comprehensive network of plasma collection centers throughout the United States, promoting better access to essential plasma-derived therapies for those who need them.
Compliance and Future Approvals
As the Houston facility opens, Kamada is preparing to submit a prior approval supplement to the FDA linked to its current Biologics License Application (BLA). This is a crucial step for ensuring regulatory compliance necessary for the center's full operation. The company also plans to file a plasma master file (PMF) with the European Medicines Agency (EMA), which will support a broader operational strategy in both the U.S. and European markets.
Focus on Innovation and Development
Kamada isn't only focused on immediate goals; they are also investing in a pipeline of innovative therapies aimed at addressing significant medical needs. One key investigational product is an inhaled AAT, specifically designed for treating AAT deficiency. This commitment to innovation marks Kamada as a forward-thinking leader in the biopharmaceutical landscape.
About Kamada
Kamada Ltd. is at the forefront of the biopharmaceutical industry, offering a wide range of products tailored for rare and severe medical conditions. The company prides itself on its ability to deliver vital therapies while consistently pushing the boundaries of research and development. With strategic partnerships and an extensive distribution network across over 30 countries, Kamada ensures that those in need have access to life-saving treatments.
Frequently Asked Questions
What is the purpose of the new plasma collection center in Houston?
The Houston center aims to boost Kamada's ability to collect both specialty and normal source plasma, which are essential for their biopharmaceutical products.
How will the new center affect Kamada's revenue?
Once the center is fully operational, it’s projected to contribute between $8 million and $10 million annually from plasma collection activities.
What types of plasma will the Houston center collect?
This center will collect normal source plasma and various specialty plasma types, including Anti-Rabies and Anti-D products.
Are there plans for additional plasma collection facilities?
Yes, Kamada is also working on a third plasma collection center in San Antonio, Texas.
What is Kamada's focus regarding innovation?
Kamada is dedicated to advancing innovative therapies, particularly for rare diseases and unmet medical needs, while continuing to grow its product portfolio.
